Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
Int J Mol Sci ; 21(15)2020 Aug 04.
Artículo en Inglés | MEDLINE | ID: mdl-32759702

RESUMEN

Vitamin A is an important regulator of immune protection, but it is often overlooked in studies of infectious disease. Vitamin A binds an array of nuclear receptors (e.g., retinoic acid receptor, peroxisome proliferator-activated receptor, retinoid X receptor) and influences the barrier and immune cells responsible for pathogen control. Children and adults in developed and developing countries are often vitamin A-deficient or insufficient, characteristics associated with poor health outcomes. To gain a better understanding of the protective mechanisms influenced by vitamin A, we examined immune factors and epithelial barriers in vitamin A deficient (VAD) mice, vitamin D deficient (VDD) mice, double deficient (VAD+VDD) mice, and mice on a vitamin-replete diet (controls). Some mice received insults, including intraperitoneal injections with complete and incomplete Freund's adjuvant (emulsified with PBS alone or with DNA + Fus-1 peptide) or intranasal inoculations with Sendai virus (SeV). Both before and after insults, the VAD and VAD+VDD mice exhibited abnormal serum immunoglobulin isotypes (e.g., elevated IgG2b levels, particularly in males) and cytokine/chemokine patterns (e.g., elevated eotaxin). Even without insult, when the VAD and VAD+VDD mice reached 3-6 months of age, they frequently exhibited opportunistic ascending bacterial urinary tract infections. There were high frequencies of nephropathy (squamous cell hyperplasia of the renal urothelium, renal scarring, and ascending pyelonephritis) and death in the VAD and VAD+VDD mice. When younger VAD mice were infected with SeV, the predominant lesion was squamous cell metaplasia of respiratory epithelium in lungs and bronchioles. Results highlight a critical role for vitamin A in the maintenance of healthy immune responses, epithelial cell integrity, and pathogen control.


Asunto(s)
Deficiencia de Vitamina A/genética , Vitamina A/genética , Deficiencia de Vitamina D/genética , Vitamina D/genética , Animales , Enfermedades Transmisibles/genética , Enfermedades Transmisibles/inmunología , Enfermedades Transmisibles/metabolismo , Muerte , Modelos Animales de Enfermedad , Humanos , Inmunoglobulinas/genética , Inmunoglobulinas/inmunología , Ratones , Ratones Noqueados , Neoplasias de Células Escamosas/genética , Neoplasias de Células Escamosas/inmunología , Neoplasias de Células Escamosas/metabolismo , Proteínas Supresoras de Tumor/genética , Vitamina A/metabolismo , Deficiencia de Vitamina A/inmunología , Deficiencia de Vitamina A/metabolismo , Vitamina D/metabolismo , Deficiencia de Vitamina D/inmunología , Deficiencia de Vitamina D/metabolismo
2.
Lab Invest ; 97(11): 1268-1270, 2017 11.
Artículo en Inglés | MEDLINE | ID: mdl-29085074

RESUMEN

Neurotrophic tyrosine kinase genes encode for the Trk-family proteins TrkA, TrkB, and TrkC, which have an important role in the development of the nervous system; however, they have been identified as oncogenic fusions in solid tumors (NTK-1, NTRK-2, and NTRK-3) and are associated with poor survival in lung cancer. These three new fusions can be detected by fluorescent in situ hybridization or next-generation sequencing in less than 5% of the lung tumors. There are several ongoing clinical trials of NTRK oncogenes in lung cancer and other tumors. The agents entrectinib (RXDX-101), a multi-kinase small molecule inhibitor that selectively inhibits NTRK1, NTRK2, and NTRK3, ROS1 and ALK, and LOXO-101, an ATP-competitive pan-NTRK inhibitor, have shown responses in patients with lung cancer with an acceptable toxicity profile. Although these oncogenic fusions are not very prevalent, the high prevalence of lung cancer makes these findings very relevant and suggests the feasibility of these oncogenes as targets in lung cancer. New data from Ozono and collaborators presented in this issue suggest that BDNF/TrkB signal promotes proliferating migratory and invasive phenotypes and cellular plasticity in squamous cell carcinoma (SCC) of the lung but that it also represents a druggable target that may bring hope to squamous lung cancer patients.


Asunto(s)
Antineoplásicos/uso terapéutico , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias de Células Escamosas/tratamiento farmacológico , Proteínas de Fusión Oncogénica/antagonistas & inhibidores , Proteínas Tirosina Quinasas Receptoras/genética , Animales , Antineoplásicos/efectos adversos , Humanos , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/metabolismo , Glicoproteínas de Membrana/antagonistas & inhibidores , Glicoproteínas de Membrana/genética , Glicoproteínas de Membrana/metabolismo , Terapia Molecular Dirigida/efectos adversos , Neoplasias de Células Escamosas/genética , Neoplasias de Células Escamosas/metabolismo , Proteínas de Fusión Oncogénica/genética , Proteínas de Fusión Oncogénica/metabolismo , Receptor trkA/antagonistas & inhibidores , Receptor trkA/genética , Receptor trkA/metabolismo , Receptor trkB/antagonistas & inhibidores , Receptor trkB/genética , Receptor trkB/metabolismo , Receptor trkC/antagonistas & inhibidores , Receptor trkC/genética , Receptor trkC/metabolismo
3.
J Nutr Biochem ; 35: 37-47, 2016 09.
Artículo en Inglés | MEDLINE | ID: mdl-27371785

RESUMEN

Aberrant activation of oncogenic signaling pathways plays a pivotal role in tumor initiation and progression. The purpose of the present study was to investigate the chemopreventive and therapeutic efficacy of blueberry in the hamster buccal pouch (HBP) carcinogenesis model based on its ability to target TGF-ß, PI3K/Akt, MAPK and NF-κB signaling and its impact on invasion and angiogenesis. Squamous cell carcinomas were induced in the HBP by 7,12-dimethylbenz[a]anthracene (DMBA). The effect of blueberry on the oncogenic signaling pathways and downstream events was analyzed by quantitative real-time PCR and immunoblotting. Experiments with the ECV304 cell line were performed to explore the mechanism by which blueberry regulates angiogenesis. Blueberry supplementation inhibited the development and progression of HBP carcinomas by abrogating TGF-ß and PI3K/Akt pathways. Although blueberry failed to influence MAPK, it suppressed NF-κB activation by preventing nuclear translocation of NF-κB p65. Blueberry also modulated the expression of the oncomiR miR-21 and the tumor suppressor let-7. Collectively, these changes induced a shift to an anti-invasive and anti-angiogenic phenotype as evidenced by downregulating matrix metalloproteinases and vascular endothelial growth factor. Blueberry also inhibited angiogenesis in ECV304 cells by suppressing migration and tube formation. The results of the present study suggest that targeting oncogenic signaling pathways that influence acquisition of cancer hallmarks is an effective strategy for chemointervention. Identification of modulatory effects on phosphorylation, intracellular localization of oncogenic transcription factors and microRNAs unraveled by the present study as key mechanisms of action of blueberry is critical from a therapeutic perspective.


Asunto(s)
Benzo(a)Antracenos/toxicidad , Arándanos Azules (Planta)/química , Suplementos Dietéticos , Frutas/química , Neoplasias de la Boca/prevención & control , Neoplasias de Células Escamosas/prevención & control , Neovascularización Patológica/prevención & control , Transducción de Señal , 9,10-Dimetil-1,2-benzantraceno , Transporte Activo de Núcleo Celular/efectos de los fármacos , Animales , Carcinógenos/toxicidad , Línea Celular Transformada , Liofilización , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Humanos , Masculino , Mesocricetus , Neoplasias de la Boca/irrigación sanguínea , Neoplasias de la Boca/metabolismo , Neoplasias de la Boca/patología , Invasividad Neoplásica , Proteínas de Neoplasias/antagonistas & inhibidores , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/metabolismo , Neoplasias de Células Escamosas/irrigación sanguínea , Neoplasias de Células Escamosas/metabolismo , Neoplasias de Células Escamosas/patología , Neovascularización Patológica/inducido químicamente , Neovascularización Patológica/metabolismo , Neovascularización Patológica/patología , Distribución Aleatoria , Transducción de Señal/efectos de los fármacos , Factor de Transcripción ReIA/antagonistas & inhibidores , Factor de Transcripción ReIA/metabolismo , Factor de Crecimiento Transformador beta/antagonistas & inhibidores , Factor de Crecimiento Transformador beta/metabolismo
4.
Biomed Res Int ; 2016: 4904016, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27123447

RESUMEN

Dracaena cinnabari Balf.f. is a red resin endemic to Socotra Island, Yemen. Although there have been several reports on its therapeutic properties, information on its cytotoxicity and anticancer effects is very limited. This study utilized a bioassay-guided fractionation approach to determine the cytotoxic and apoptosis-inducing effects of D. cinnabari on human oral squamous cell carcinoma (OSCC). The cytotoxic effects of D. cinnabari crude extract were observed in a panel of OSCC cell lines and were most pronounced in H400. Only fractions DCc and DCd were active on H400 cells; subfractions DCc15 and DCd16 exhibited the greatest cytotoxicity against H400 cells and D. cinnabari inhibited cells proliferation in a time-dependent manner. This was achieved primarily via apoptosis where externalization of phospholipid phosphatidylserine was observed using DAPI/Annexin V fluorescence double staining mechanism studied through mitochondrial membrane potential assay cytochrome c enzyme-linked immunosorbent and caspases activities revealed depolarization of mitochondrial membrane potential (MMP) and significant activation of caspases 9 and 3/7, concomitant with S phase arrest. Apoptotic proteins array suggested that MMP was regulated by Bcl-2 proteins family as results demonstrated an upregulation of Bax, Bad, and Bid as well as downregulation of Bcl-2. Hence, D. cinnabari has the potential to be developed as an anticancer agent.


Asunto(s)
Apoptosis/efectos de los fármacos , Caspasas/metabolismo , Puntos de Control del Ciclo Celular/efectos de los fármacos , Dracaena/química , Mitocondrias/metabolismo , Neoplasias de la Boca/patología , Neoplasias de Células Escamosas/patología , Extractos Vegetales/farmacología , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Bioensayo , Proliferación Celular/efectos de los fármacos , Forma de la Célula/efectos de los fármacos , Fraccionamiento Químico , Citocromos c/metabolismo , Fragmentación del ADN/efectos de los fármacos , Fibroblastos/efectos de los fármacos , Humanos , Concentración 50 Inhibidora , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Mitocondrias/efectos de los fármacos , Neoplasias de la Boca/metabolismo , Neoplasias de Células Escamosas/metabolismo , Nucleosomas/efectos de los fármacos , Nucleosomas/metabolismo , Fosfatidilserinas/metabolismo , Fase S/efectos de los fármacos , Transducción de Señal/efectos de los fármacos
5.
Am J Chin Med ; 41(3): 683-96, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23711149

RESUMEN

Oral cancer is a common malignancy associated with high morbidity and mortality. While p38 MAPK is reported to be involved in different cellular activities such as proliferation and differentiation, reports rarely define the roles of the individual members of the p38 MAPK family in cancer. We used two unique cell lines developed by our lab representing chemically induced oral cancer cells (T28) and non-tumor cells (N28) obtained from tissues surrounding the induced cancer as a model to screen out whether p38 MAPK is involved in the malignant transformation processes. The results suggest an association between p38ß not p38α and oral cancer development. Additionally, the anti-cancer activity of thymoquinone (TQ) was screened out and we found evidences suggesting that the anti-tumor activity of TQ may be attributed to the downregulation of p38ß MAPK.


Asunto(s)
Apoptosis/efectos de los fármacos , Benzoquinonas/farmacología , Proteína Quinasa 11 Activada por Mitógenos/antagonistas & inhibidores , Neoplasias de la Boca/tratamiento farmacológico , Neoplasias de Células Escamosas/tratamiento farmacológico , Nigella sativa/química , Extractos Vegetales/farmacología , Animales , Anticarcinógenos/farmacología , Anticarcinógenos/uso terapéutico , Antineoplásicos Fitogénicos/farmacología , Antineoplásicos Fitogénicos/uso terapéutico , Benzoquinonas/uso terapéutico , Línea Celular , Línea Celular Tumoral , Regulación hacia Abajo , Ratones , Ratones Endogámicos C57BL , Proteína Quinasa 14 Activada por Mitógenos/metabolismo , Mucosa Bucal/citología , Mucosa Bucal/efectos de los fármacos , Neoplasias de la Boca/metabolismo , Neoplasias de Células Escamosas/metabolismo , Fitoterapia , Extractos Vegetales/uso terapéutico
6.
J Agric Food Chem ; 60(34): 8395-403, 2012 Aug 29.
Artículo en Inglés | MEDLINE | ID: mdl-22827697

RESUMEN

Epithelial-to-mesenchymal transition (EMT) in cancer cells is considered to be a prerequisite for acquiring invasive/migratory phenotype and subsequent metastasis. This study provides molecular evidence associated with the antimetastatic effect of black tea polyphenol extracts (BTE), which contain polyphenols including gallic acid, gallocatechin, catechin, epigallocatechin-3-gallate, epicatechin-3-gallate, and theaflavin 3,3'-digallate, in an an oral squamous cell culture system by showing a nearly complete inhibition on the invasion (p < 0.001) of SCC-4 cells via reduced activities of MMP-2 (p < 0.001) and u-PA (p < 0.001). Immunoblot was performed to find that BTE could induce up-regulation of epithelial markers such as E-cadherin and inhibit mesenchymal markers such as snail-1 and vimentin. BTE inhibited p-FAK and p-paxillin, indicating the anti-EMT effect of BTE in oral squamous cell carcinoma. BTE was evidenced by its inhibition of the tumor growth of SCC-4 cells via cancer cell xenografted nude mice mode. These results suggested that BTE could reduce invasion by reversing EMT in human oral cancer cells.


Asunto(s)
Camellia sinensis/química , Transición Epitelial-Mesenquimal/efectos de los fármacos , Neoplasias de la Boca/tratamiento farmacológico , Neoplasias de la Boca/patología , Neoplasias de Células Escamosas/tratamiento farmacológico , Polifenoles/farmacología , Animales , Cadherinas/metabolismo , Movimiento Celular/efectos de los fármacos , Transición Epitelial-Mesenquimal/fisiología , Humanos , Metaloproteinasa 2 de la Matriz/metabolismo , Ratones , Ratones Desnudos , Neoplasias de la Boca/metabolismo , Neoplasias de Células Escamosas/metabolismo , Neoplasias de Células Escamosas/patología , Regiones Promotoras Genéticas/efectos de los fármacos , Inhibidores de Proteasas/farmacología , Células Tumorales Cultivadas , Activador de Plasminógeno de Tipo Uroquinasa/genética , Activador de Plasminógeno de Tipo Uroquinasa/metabolismo , Vimentina/antagonistas & inhibidores , Vimentina/metabolismo , Ensayos Antitumor por Modelo de Xenoinjerto
7.
Expert Rev Anticancer Ther ; 11(4): 511-24, 2011 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-21504318

RESUMEN

The majority of the head and neck cancers are squamous cell carcinomas, which commonly overexpress the EGF receptor (EGFR). Cetuximab is a chimeric monoclonal antibody that binds with high affinity to the extracellular domain of EGFR, and in addition induces antibody-dependent cellular cytoxicity. In a randomized Phase III trial in patients with locoregionally advanced squamous cell carcinoma of the head and neck, the addition of cetuximab to radiotherapy prolonged the median time of locoregional control from 14.9 to 24.4 months and increased the median overall survival from 29.3 to 49.0 months. In patients with platinum-refractory recurrent and/or metastatic disease, the objective response and disease-control rates in various studies ranged from 10 to 13% and from 46 to 56%, respectively. In the EXTREME trial, the addition of cetuximab to platinum/5-fluorouracil as first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck not only led to significant improvements in survival, response rate and disease control, but also induced a better symptom control in comparison with that observed with platinum/5-fluorouracil alone.


Asunto(s)
Anticuerpos Monoclonales/farmacología , Anticuerpos Monoclonales/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Animales , Anticuerpos Monoclonales/administración & dosificación , Anticuerpos Monoclonales/farmacocinética , Anticuerpos Monoclonales Humanizados , Carcinoma/tratamiento farmacológico , Carcinoma/metabolismo , Carcinoma/radioterapia , Carcinoma de Células Escamosas , Cetuximab , Quimioterapia Adyuvante , Ensayos Clínicos como Asunto , Receptores ErbB/antagonistas & inhibidores , Fluorouracilo/administración & dosificación , Neoplasias de Cabeza y Cuello/tratamiento farmacológico , Neoplasias de Cabeza y Cuello/metabolismo , Neoplasias de Cabeza y Cuello/radioterapia , Humanos , Neoplasias de Células Escamosas/tratamiento farmacológico , Neoplasias de Células Escamosas/metabolismo , Neoplasias de Células Escamosas/radioterapia , Compuestos Organoplatinos/administración & dosificación , Carcinoma de Células Escamosas de Cabeza y Cuello
8.
Oncol Rep ; 25(3): 729-37, 2011 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-21165582

RESUMEN

Metastatic squamous cell carcinoma of the head and neck (SCCHN) has been shown to express chemokine receptor 7 (CCR7), which activates phosphoinositide-3 kinase (PI3K) to promote invasion and survival of SCCHN cells. We hypothesized that Cdc42 might be involved in the CCR7-PI3K pathway. Adhesion assays, migration assays, immunofluorescence staining, Western blotting and immunohistochemical analysis were used to find whether Cdc42 can be activated by CCL19 (the CCR7 ligand) and its role in SCCHN. Results showed that CCL19 induced polarized localization of Cdc42 and actin polymerization in the leading edge of migrating cells. The level of activated membrane-bound Cdc42 was elevated, as measured by the GTPase activity pull-down assay. The increased membrane localization and membrane-bound activity of Cdc42 were abolished by CCR7 and PI3K inhibition, indicating the involvement of Cdc42 in the CCR7-PI3K cascade. Knockdown of Cdc42 by small interfering RNA (siRNA) led to significant reduction in the activation of Rac, filamentous actin (F-actin) accumulation as well as in the migration and invasion induced by CCL19. Taken together, our data indicate the important role played by Cdc42 in CCL19-induced migration and invasion of SCCHN cells.


Asunto(s)
Quimiocina CCL19/farmacología , Fosfatidilinositol 3-Quinasas/fisiología , Receptores CCR7/agonistas , Receptores CCR7/fisiología , Proteína de Unión al GTP cdc42/fisiología , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma/genética , Carcinoma/metabolismo , Carcinoma/patología , Carcinoma de Células Escamosas , Movimiento Celular/efectos de los fármacos , Movimiento Celular/genética , Quimiocina CCL19/metabolismo , Evaluación Preclínica de Medicamentos , Femenino , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Neoplasias de Cabeza y Cuello/genética , Neoplasias de Cabeza y Cuello/metabolismo , Neoplasias de Cabeza y Cuello/patología , Humanos , Masculino , Persona de Mediana Edad , Invasividad Neoplásica , Metástasis de la Neoplasia , Neoplasias de Células Escamosas/genética , Neoplasias de Células Escamosas/metabolismo , Neoplasias de Células Escamosas/patología , Fosfatidilinositol 3-Quinasas/metabolismo , ARN Interferente Pequeño/farmacología , Receptores CCR7/metabolismo , Transducción de Señal/efectos de los fármacos , Transducción de Señal/genética , Transducción de Señal/fisiología , Carcinoma de Células Escamosas de Cabeza y Cuello , Células Tumorales Cultivadas , Proteína de Unión al GTP cdc42/antagonistas & inhibidores , Proteína de Unión al GTP cdc42/genética , Proteína de Unión al GTP cdc42/metabolismo
9.
Oncol Rep ; 21(5): 1297-305, 2009 May.
Artículo en Inglés | MEDLINE | ID: mdl-19360307

RESUMEN

PC-Spes is a preparation of eight Chinese herbs, which exhibits antiproliferative and antitumour activity in diverse cancer types in vivo and in vitro. We exposed the head and neck squamous carcinoma cell lines (HNSCC) FADU, HLaC79 and HLaC79-clone1, which is a paclitaxel-resistant descendant of HLaC79, as well as primary cultured mucosal keratinocytes to increasing concentrations of paclitaxel and/or PC-Spes. Growth inhibition was measured using the MTT assay. While FADU and HLaC79 were growth inhibited by paclitaxel, HLaC79-clone1 cells proved to be resistant against paclitaxel up to doses of 100 nM, whereas all three cell lines were growth inhibited by PC-Spes. Interestingly primary keratinocytes were less sensitive to PC-Spes, they even showed better survivel at low PC-Spes doses. Furthermore, we analyzed cell cycle distribution, apoptosis and tubulin expression level and polymerization status in the HNSCC cell lines. PC-Spes caused a slight decrease of cells in S/G2 phase in HLaC79-clone1. In FADU and HLaC79 cells the cell cycle was shifted towards S/G2 phase as expected. Apoptosis was initiated in all three cell lines by PC-Spes, in mucosal keratinocytes, however, it was triggered less distinctively. In summary, PC-Spes revealed distinct growth inhibition in a paclitaxel-resistant cell line, whereas primary mucosal keratinocytes were less sensitive. PC-Spes might therefore provide a therapeutical approach in chemoresistant head and neck cancer.


Asunto(s)
Antineoplásicos Fitogénicos/farmacología , Medicamentos Herbarios Chinos/farmacología , Queratinocitos/efectos de los fármacos , Neoplasias Laríngeas/tratamiento farmacológico , Neoplasias de Células Escamosas/tratamiento farmacológico , Animales , Apoptosis/efectos de los fármacos , Ciclo Celular/efectos de los fármacos , División Celular/efectos de los fármacos , Línea Celular Tumoral , Resistencia a Antineoplásicos , Técnica del Anticuerpo Fluorescente , Humanos , Queratinocitos/metabolismo , Neoplasias Laríngeas/metabolismo , Neoplasias Laríngeas/patología , Neoplasias de Células Escamosas/metabolismo , Neoplasias de Células Escamosas/patología , Paclitaxel/farmacología , Tubulina (Proteína)/biosíntesis , Tubulina (Proteína)/metabolismo
10.
Mol Cell Biol ; 28(1): 326-32, 2008 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-17967887

RESUMEN

Aquaporin-3 (AQP3) is a water/glycerol-transporting protein expressed strongly at the plasma membranes of basal epidermal cells in skin. We found that human skin squamous cell carcinoma strongly overexpresses AQP3. A novel role for AQP3 in skin tumorigenesis was discovered using mice with targeted AQP3 gene disruption. We found that AQP3-null mice were remarkably resistant to the development of skin tumors following exposure to a tumor initiator and phorbol ester promoter. Though tumor initiator challenge produced comparable apoptotic responses in wild-type and AQP3-null mice, promoter-induced cell proliferation was greatly impaired in the AQP3-null epidermis. Reductions of epidermal cell glycerol, its metabolite glycerol-3-phosphate, and ATP were found in AQP3 deficiency without impairment of mitochondrial function. Glycerol supplementation corrected the reduced proliferation and ATP content in AQP3 deficiency, with cellular glycerol, ATP, and proliferative ability being closely correlated. Our data suggest involvement of AQP3-facilitated glycerol transport in epidermal cell proliferation and tumorigenesis by a novel mechanism implicating cellular glycerol as a key determinant of cellular ATP energy. AQP3 may thus be an important determinant in skin tumorigenesis and hence a novel target for tumor prevention and therapy.


Asunto(s)
Acuaporina 3/metabolismo , Transformación Celular Neoplásica/metabolismo , Transformación Celular Neoplásica/patología , Epidermis/metabolismo , Epidermis/patología , Neoplasias Cutáneas/metabolismo , Neoplasias Cutáneas/prevención & control , Adenosina Trifosfato/metabolismo , Animales , Acuaporina 3/deficiencia , Acuaporina 3/genética , Proliferación Celular/efectos de los fármacos , Transformación Celular Neoplásica/genética , Células Cultivadas/efectos de los fármacos , Glicerol/farmacología , Humanos , Queratinocitos/metabolismo , Ratones , Ratones Noqueados , Neoplasias de Células Escamosas/genética , Neoplasias de Células Escamosas/metabolismo , Neoplasias Cutáneas/genética , Neoplasias Cutáneas/patología , Acetato de Tetradecanoilforbol/farmacología
11.
Acta Otolaryngol ; 124(9): 1078-85, 2004 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-15513553

RESUMEN

OBJECTIVE: High rates of local recurrence and distant metastases following surgery of high-grade head and neck squamous cell carcinoma (HNSCC) necessitate the use of adjuvant systemic treatment. Radioimmunotargeting might be a possible treatment modality in this case. The nuclear properties of 131I make it a suitable isotope for treatment of minimal residual disease and small metastases, but the conventional radioiodine label has poor cellular retention and its radiocatabolites accumulate in the thyroid. We attempted to overcome these problems by using closo-dodecaborate derivatives for attachment of radioiodine. MATERIAL AND METHODS: We investigated the feasibility of targeting an SCC25 HNSCC xenograft in vivo using a benzylisothiocyanate derivative of closo-dodecaborate (DABI) as radioiodine linker and the chimeric anti-CD44v6 antibody U36. 125I was used in biodistribution studies. RESULTS: The use of DABI enabled tumor targeting and decreased the radioactivity uptake of the thyroid. CONCLUSION: Tumor localization of DABI-labeled U36 was similar to its para-iodobenzoate-labeled counterpart, presumably due to the strong dependence of targeting efficiency on tumor size.


Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Neoplasias de Cabeza y Cuello/radioterapia , Radioisótopos de Yodo/uso terapéutico , Neoplasias de Células Escamosas/radioterapia , Radioinmunoterapia/métodos , Animales , Anticuerpos Monoclonales/farmacocinética , Área Bajo la Curva , Compuestos de Boro/farmacocinética , Línea Celular Tumoral/efectos de la radiación , Neoplasias de Cabeza y Cuello/metabolismo , Humanos , Radioisótopos de Yodo/farmacocinética , Ratones , Ratones Desnudos , Neoplasias de Células Escamosas/metabolismo , Distribución Tisular , Trasplante Heterólogo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA